Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma

verfasst von: Jian Yin, Peng Hou, Zhiqiang Wu, Tao Wang, Yanxiao Nie

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Aiming to find novel non-invasive biomarkers with high accuracy for the detention of early-stage hepatocellular carcinoma (HCC), we examined the predictive power of two microRNAs (miR; miR-375 and miR-199a-3p) as potential biomarkers in early-stage HCC. A total of 234 serum samples (78 samples from HCC patients, 156 samples from healthy controls) were collected. We measured the levels of the two mature microRNAs (miRNAs) (miR-375 and miR-199a-3p) with probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in all subjects. In addition, the correlation between the expression levels of two miRs and clinicopathological factors was explored. Receiver operating characteristic curve (ROC) analyses revealed that the two serum miRs could be promising biomarkers for HCC, with relatively high area under the curve (AUC) values as follows: miR-375, 0. 637 with 95 % confidence interval (CI) of 0.560–0.741; miR-199a-3p, 0. 883 with 95 % CI of 0.827–0.938. Stratified analyses indicated that circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results.
Literatur
1.
Zurück zum Zitat Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.CrossRefPubMed Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.CrossRefPubMed
2.
Zurück zum Zitat Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31–9.CrossRefPubMedPubMedCentral Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31–9.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Asia-Pacific Working Party on Prevention of Hepatocellular C Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010:25:657-663. Asia-Pacific Working Party on Prevention of Hepatocellular C Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010:25:657-663.
4.
Zurück zum Zitat Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346–53.CrossRefPubMed Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346–53.CrossRefPubMed
5.
Zurück zum Zitat Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–80.CrossRefPubMedPubMedCentral Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–80.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat. 2014;21:357–65.CrossRefPubMed Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat. 2014;21:357–65.CrossRefPubMed
7.
Zurück zum Zitat Bao YX, Cao Q, Yang Y, Mao R, Xiao L, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013;8:197.CrossRefPubMedPubMedCentral Bao YX, Cao Q, Yang Y, Mao R, Xiao L, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013;8:197.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomarker Res. 2013;1:10.CrossRef Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomarker Res. 2013;1:10.CrossRef
9.
Zurück zum Zitat Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentral Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Han LL, Nan HC, Tian T, Guo H, Hu TH, et al. Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncol Rep. 2014;31:2569–78.PubMed Han LL, Nan HC, Tian T, Guo H, Hu TH, et al. Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncol Rep. 2014;31:2569–78.PubMed
11.
Zurück zum Zitat Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, et al. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S616–624.CrossRefPubMed Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, et al. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S616–624.CrossRefPubMed
12.
Zurück zum Zitat Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, et al. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res: Off J Japan Soc Hepatol. 2014. Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, et al. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res: Off J Japan Soc Hepatol. 2014.
13.
Zurück zum Zitat Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27:255–68.CrossRefPubMed Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27:255–68.CrossRefPubMed
14.
Zurück zum Zitat Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28:3926–36.CrossRefPubMed Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28:3926–36.CrossRefPubMed
15.
Zurück zum Zitat Cho W, Ziogas DE, Katsios C, Roukos DH. Emerging personalized oncology: sequencing and systems strategies. Future Oncol. 2012;8:637–41.CrossRefPubMed Cho W, Ziogas DE, Katsios C, Roukos DH. Emerging personalized oncology: sequencing and systems strategies. Future Oncol. 2012;8:637–41.CrossRefPubMed
16.
Zurück zum Zitat Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.CrossRefPubMed Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.CrossRefPubMed
17.
Zurück zum Zitat Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455–8.CrossRefPubMed Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455–8.CrossRefPubMed
18.
Zurück zum Zitat Krawczyk M, Mullenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669–81.CrossRefPubMed Krawczyk M, Mullenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669–81.CrossRefPubMed
19.
Zurück zum Zitat Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49:460–70.CrossRefPubMed Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49:460–70.CrossRefPubMed
20.
Zurück zum Zitat Dai Z, Zhou J, Qiu SJ, Liu YK, Fan J. Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. Electrophoresis. 2009;30:2957–66.CrossRefPubMed Dai Z, Zhou J, Qiu SJ, Liu YK, Fan J. Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. Electrophoresis. 2009;30:2957–66.CrossRefPubMed
21.
Zurück zum Zitat Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed
24.
Zurück zum Zitat Liu F, Xiong Y, Zhao Y, Tao L, Zhang Z, et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray. Diagn Pathol. 2013;8:158.PubMedPubMedCentral Liu F, Xiong Y, Zhao Y, Tao L, Zhang Z, et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray. Diagn Pathol. 2013;8:158.PubMedPubMedCentral
25.
Zurück zum Zitat Wang W, Li F, Zhang Y, Tu Y, Yang Q, et al. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013;8:102.PubMedPubMedCentral Wang W, Li F, Zhang Y, Tu Y, Yang Q, et al. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013;8:102.PubMedPubMedCentral
26.
Zurück zum Zitat Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014;41:4513–9.CrossRefPubMed Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014;41:4513–9.CrossRefPubMed
27.
Zurück zum Zitat Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60:135–42.CrossRefPubMedPubMedCentral Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60:135–42.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Luo J, Chen M, Huang H, Yuan T, Zhang M, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. OncoTargets Ther. 2013;6:577–83. Luo J, Chen M, Huang H, Yuan T, Zhang M, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. OncoTargets Ther. 2013;6:577–83.
29.
Zurück zum Zitat Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.CrossRefPubMedPubMedCentral Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama. 2007;297:1901–8.CrossRefPubMed Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama. 2007;297:1901–8.CrossRefPubMed
31.
Zurück zum Zitat Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5:2513–28.CrossRefPubMedPubMedCentral Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5:2513–28.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Wan D, He S, Xie B, Xu G, Gu W, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol. 2013;30:378.CrossRefPubMed Wan D, He S, Xie B, Xu G, Gu W, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol. 2013;30:378.CrossRefPubMed
33.
Zurück zum Zitat Naugler WE, Schwartz JM. Hepatocellular carcinoma. Dis-a-Month: DM. 2008;54:432–44.CrossRef Naugler WE, Schwartz JM. Hepatocellular carcinoma. Dis-a-Month: DM. 2008;54:432–44.CrossRef
34.
Zurück zum Zitat Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22.CrossRefPubMed Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22.CrossRefPubMed
35.
Zurück zum Zitat Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.CrossRefPubMed Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.CrossRefPubMed
36.
Zurück zum Zitat Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;9, CD002799. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;9, CD002799.
37.
Zurück zum Zitat He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Gen. 2004;5:522–31.CrossRef He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Gen. 2004;5:522–31.CrossRef
38.
Zurück zum Zitat Geng Q, Fan T, Zhang B, Wang W, Xu Y, et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir Res. 2014;15:149.CrossRefPubMedPubMedCentral Geng Q, Fan T, Zhang B, Wang W, Xu Y, et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir Res. 2014;15:149.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–30.CrossRefPubMed Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–30.CrossRefPubMed
40.
Zurück zum Zitat Zhou J, Song S, He S, Zhu X, Zhang Y, et al. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33:950–6.PubMed Zhou J, Song S, He S, Zhu X, Zhang Y, et al. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33:950–6.PubMed
41.
Zurück zum Zitat He XX, Chang Y, Meng FY, Wang MY, Xie QH, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.CrossRefPubMed He XX, Chang Y, Meng FY, Wang MY, Xie QH, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.CrossRefPubMed
42.
Zurück zum Zitat Ding L, Xu Y, Zhang W, Deng Y, Si M, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20:784–93.CrossRefPubMed Ding L, Xu Y, Zhang W, Deng Y, Si M, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20:784–93.CrossRefPubMed
43.
Zurück zum Zitat Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:6192–200.CrossRef Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:6192–200.CrossRef
44.
Zurück zum Zitat de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70:9175–84.CrossRefPubMed de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70:9175–84.CrossRefPubMed
45.
Zurück zum Zitat Yu H, Jiang L, Sun C, Li Guo L, Lin M, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534:60–5.CrossRefPubMed Yu H, Jiang L, Sun C, Li Guo L, Lin M, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534:60–5.CrossRefPubMed
46.
Zurück zum Zitat Shao Y, Geng Y, Gu W, Huang J, Ning Z, et al. Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers. 2014;2014:626185.CrossRefPubMedPubMedCentral Shao Y, Geng Y, Gu W, Huang J, Ning Z, et al. Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers. 2014;2014:626185.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41:1257–66.CrossRefPubMed Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41:1257–66.CrossRefPubMed
48.
Zurück zum Zitat Chang C, Shi H, Wang C, Wang J, Geng N, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 2012;531:204–8.CrossRefPubMed Chang C, Shi H, Wang C, Wang J, Geng N, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 2012;531:204–8.CrossRefPubMed
49.
Zurück zum Zitat Li J, Li X, Li Y, Yang H, Wang L, et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One. 2013;8:e53582.CrossRefPubMedPubMedCentral Li J, Li X, Li Y, Yang H, Wang L, et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One. 2013;8:e53582.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Kong KL, Kwong DL, Chan TH, Law SY, Chen L, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.CrossRefPubMed Kong KL, Kwong DL, Chan TH, Law SY, Chen L, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.CrossRefPubMed
51.
Zurück zum Zitat Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, et al. miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res. 2014;6:604–13.PubMedPubMedCentral Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, et al. miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res. 2014;6:604–13.PubMedPubMedCentral
52.
Zurück zum Zitat Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:419–27.CrossRef Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:419–27.CrossRef
53.
Zurück zum Zitat Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.CrossRefPubMed Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.CrossRefPubMed
54.
Zurück zum Zitat Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.CrossRefPubMed Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.CrossRefPubMed
Metadaten
Titel
Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma
verfasst von
Jian Yin
Peng Hou
Zhiqiang Wu
Tao Wang
Yanxiao Nie
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3092-0

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.